Download PDF
Exp Clin Endocrinol Diabetes 2017; 125(04): 234-240
DOI: 10.1055/s-0042-122138
Article
© Georg Thieme Verlag KG Stuttgart · New York

Osteocalcin Improves Metabolic Profiles, Body Composition and Arterial Stiffening in an Induced Diabetic Rat Model

Lingning Huang
1   Endocrinology Department, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China
,
Liyong Yang
1   Endocrinology Department, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China
,
Li Luo
2   Fujian Hypertension Research Institute, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China
,
Peiwen Wu
1   Endocrinology Department, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China
,
Sunjie Yan
1   Endocrinology Department, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China
› Author Affiliations
Further Information

Publication History

received 17 October 2016
first decision 24 November 2016

accepted 24 November 2016

Publication Date:
10 January 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Recent studies have demonstrated the benefits of osteocalcin (OCN) on glucose homeostasis and metabolic dysregulation. However, its role in body composition and vascular function remains unknown. This study was designed to examine changes in metabolic parameters and body composition as well as arterial stiffness after OCN treatment in type 2 diabetic rats. Adult male Sprague Dawley (SD) rats were fed chow or high fat diet (HFD) for 8 weeks, and then diabetes was induced with an injection of low-dose streptozotocin (STZ) and treated daily with intraperitoneal injections of OCN for 12 weeks. Our data showed that OCN treatment improved glucose homeostasis and lipid metabolism. Further analysis revealed that OCN treatment resulted in increased insulin sensitivity. In addition, untreated diabetic rats experienced significant weight loss, whereas OCN-treated rats better maintained body weight (300.75±38.14 g vs. 335.50±23.70, p=0.005). OCN also changed body composition, as evidenced by reduced body fat mass, specifically abdominal fat mass. OCN-treated diabetic rats also demonstrated decreased pulse-wave velocity, indicating of improved arterial stiffness. Taken together, our findings in the current study revealed that OCN therapy prevents arteriosclerosis in an induced diabetic rat model by exerting beneficial effects on glucose levels, insulin sensitivity, lipid metabolites, and body composition changes.

Key words

type 2 diabetes mellitus - atherosclerosis - osteocalcin - body composition - pulse wave velocity
 

  • References

  • 1 Control CfD, Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services; 2014. 2014
    Google Scholar
  • 2 Cansu GB, Sari R, Yilmaz N et al. Markers of subclinical cardiovascular disease in nonfunctional adrenal incidentaloma patients without traditional cardiovascular risk factors. Exp Clin Endocrinol Diabetes 2016; 29: 29
    PubMedGoogle Scholar
  • 3 World Health Organization. Cardiovascular diseases (CVDs) fact sheet. In: Geneva: WHO; 2015
    Google Scholar
  • 4 Zhong N, Xu B, Cui R et al. Positive correlation between serum osteocalcin and testosterone in male hyperthyroidism patients with high bone turnover. Exp Clin Endocrinol Diabetes 2016; 124: 452-456
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Lee NK, Sowa H, Hinoi E et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456-469
    CrossrefPubMedGoogle Scholar
  • 6 Ducy P, Desbois C, Boyce B et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382: 448-452
    CrossrefPubMedGoogle Scholar
  • 7 Yang R, Ma X, Dou J et al. Relationship between serum osteocalcin levels and carotid intima-media thickness in Chinese postmenopausal women. Menopause 2013; 20: 1194-1199
    CrossrefPubMedGoogle Scholar
  • 8 Yang R, Ma X, Pan X et al. Serum osteocalcin levels in relation to metabolic syndrome in Chinese postmenopausal women. Menopause 2013; 20: 548-553
    PubMedGoogle Scholar
  • 9 Kanazawa I, Yamaguchi T, Tada Y et al. . Bone 2011; 48: 720-725
    CrossrefPubMedGoogle Scholar
  • 10 Alfadda AA, Masood A, Shaik SA et al. Association between osteocalcin, metabolic syndrome, and cardiovascular risk factors: role of total and undercarboxylated osteocalcin in patients with type 2 diabetes. Int J Endocrinol 2013; 2013
    PubMed
  • 11 Dou J, Li H, Ma X et al. Osteocalcin attenuates high fat diet-induced impairment of endothelium-dependent relaxation through Akt/eNOS-dependent pathway. Cardiovasc diabetol 2014; 13: 1
    CrossrefPubMedGoogle Scholar
  • 12 Fox CS. Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study. Trends Cardiovasc Med 2010; 20: 90-95
    CrossrefPubMedGoogle Scholar
  • 13 Mulè G, Cottone S, Cusimano P et al. The association of microalbuminuria with aortic stiffness is independent of C-reactive protein in essential hypertension. Am J Hypertens 2009; 22: 1041-1047
    CrossrefPubMedGoogle Scholar
  • 14 Ishimura E, Taniwaki H, Tsuchida T et al. Urinary albumin excretion associated with arterial wall stiffness rather than thickness in type 2 diabetic patients. J Nephrol 2007; 20: 204-211
    PubMedGoogle Scholar
  • 15 Coutinho T, Turner ST, Kullo IJ. Aortic pulse wave velocity is associated with measures of subclinical target organ damage. JACC: Cardiovasc Imag 2011; 4: 754-761
    CrossrefPubMedGoogle Scholar
  • 16 Cruickshank K, Riste L, Anderson SG et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance an integrated index of vascular function?. Circulation 2002; 106: 2085-2090
    CrossrefPubMedGoogle Scholar
  • 17 Kanazawa I, Yamaguchi T, Yamamoto M et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrin Metabol 2009; 94: 45-49
    CrossrefPubMedGoogle Scholar
  • 18 Laverdy OG, Hueb WA, Sprandel MC et al. Effects of glycemic control upon serum lipids and lipid transfers to HDL in patients with type 2 diabetes mellitus: novel findings in unesterified cholesterol status. Exp Clin Endocrinol Diabetes 2015; 123: 232-239
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Chen W, Wilson JL, Khaksari M et al. Abdominal fat analyzed by DEXA scan reflects visceral body fat and improves the phenotype description and the assessment of metabolic risk in mice. Am J Physiol Endocrinol and Metabol 2012; 303: E635-E643
    PubMedGoogle Scholar
  • 20 Salum E, Kampus P, Zilmer M et al. Effect of vitamin D on aortic remodeling in streptozotocin-induced diabetes. Cardiovasc diabetol 2012; 11: 1
    CrossrefPubMedGoogle Scholar
  • 21 Cosson E, Herisse M, Laude D et al. Aortic stiffness and pulse pressure amplification in Wistar-Kyoto and spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2007; 292: H2506-H2512
    CrossrefPubMedGoogle Scholar
  • 22 Mei-rong L, Jing-an L, Sun-jie Y. Effects of pioglitazone on MC3T3-E1 osteoblasts in high glucose condition and its mechanism. Chinese J New Drugs Clin Remedies 2011; 1: 24-29
    PubMedGoogle Scholar
  • 23 Feng L, Shen X, Yan S. The effects of pioglitazone on proliferation, apoptosis and expressions of functional protein in normal osteoblastic cells MC3T3-E1. Bone 2010; 47: S414-S415
    PubMedGoogle Scholar
  • 24 Hill H, Grams J, Walton R et al. Carboxylated and uncarboxylated forms of osteocalcin directly modulate the glucose transport system and inflammation in adipocytes. Horm Metab Res 2014; 46: 341-347
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Mizokami A, Yasutake Y, Gao J et al. Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PloS one 2013; 8: e57375
    CrossrefPubMedGoogle Scholar
  • 26 Mizokami A, Yasutake Y, Higashi S et al. Oral administration of osteocalcin improves glucose utilization by stimulating glucagon-like peptide-1 secretion. Bone 2014; 69: 68-79
    CrossrefPubMedGoogle Scholar
  • 27 Sandeep S, Gokulakrishnan K, Velmurugan K et al. Visceral & subcutaneous abdominal fat in relation to insulin resistance & metabolic syndrome in non-diabetic south Indians. 2010; 189-191
    PubMedGoogle Scholar
  • 28 Bouchi R, Takeuchi T, Akihisa M et al. High visceral fat with low subcutaneous fat accumulation as a determinant of atherosclerosis in patients with type 2 diabetes. Cardiovasc diabetol 2015; 14: 1
    CrossrefPubMedGoogle Scholar
  • 29 Nazim J, Malachowska B, Fendler W et al. Low-grade Albuminuria and Risk Factors of Atherosclerosis in Children with in Type 1 Diabetes. Exp Clin Endocrinol Diabetes 2016; 124: 16-21
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Al-Daghri NM, Al-Attas OS, Wani K et al. Sensitivity of various adiposity indices in identifying cardiometabolic diseases in Arab adults. Cardiovasc diabetol 2015; 14: 1
    CrossrefPubMedGoogle Scholar
  • 31 Kindblom JM, Ohlsson C, Ljunggren Ö et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Mineral Res 2009; 24: 785-791
    CrossrefPubMedGoogle Scholar
  • 32 Kanazawa I, Yamaguchi T, Yamauchi M et al. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 2011; 22: 187-194
    CrossrefPubMedGoogle Scholar
  • 33 Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell metab 2011; 14: 575-585
    CrossrefPubMedGoogle Scholar
  • 34 Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest 2006; 116: 1813-1822
    CrossrefPubMedGoogle Scholar